S
Sebastian George
Researcher at University of California, Los Angeles
Publications - 3
Citations - 1772
Sebastian George is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Bone pain & Multiple myeloma. The author has an hindex of 3, co-authored 3 publications receiving 1752 citations.
Papers
More filters
Journal ArticleDOI
Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
James R. Berenson,Alan Lichtenstein,Lester Porter,Meletios A. Dimopoulos,Roldolfo Bordoni,Sebastian George,Allan Lipton,Alan Keller,O. F. Ballester,Michael J. Kovacs,Hilary A. Blacklock,Richard Bell,Joseph F. Simeone,Dirk J. Reitsma,Maika Heffernan,John J. Seaman,Robert Knight +16 more
TL;DR: Monthly infusions of pamidronate provide significant protection against skeletal complications and improve the quality of life of patients with stage III multiple myeloma.
Journal ArticleDOI
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.
James R. Berenson,Alan Lichtenstein,Lester Porter,Meletios A. Dimopoulos,Roldolfo Bordoni,Sebastian George,Alan Lipton,Alan Keller,O. F. Ballester,Michael J. Kovacs,Hillary Blacklock,Richard Bryan Bell,Joseph F. Simeone,Dirk J. Reitsma,Maika Heffernan,John J. Seaman,Rob Knight +16 more
TL;DR: Long-term monthly infusions of pamidronate as an adjunct to chemotherapy are superior to chemotherapy alone in reducing skeletal events in stage III multiple myeloma patients, and may improve the survival of patients on salvage therapy.
Journal ArticleDOI
Intravenous pamidronate disodium treatment of bone metastases in patients with breast cancer. A dose-seeking study.
Donna Glover,Alan Lipton,Alan Keller,Antonius A. Miller,Scott M. Browning,Robert J. Fram,Sebastian George,Kenneth Zelenakas,Richard S. Macerata,John J. Seaman +9 more
TL;DR: Pamidronate disodium, a bisphosphonate, may prove helpful in the palliative treatment of bone metastases in patients with breast cancer as demonstrated in this multicenter, dose‐ranging trial.